Fudan University
1,564
391
455
318
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.9%
29 terminated/withdrawn out of 1564 trials
91.6%
+5.1% vs industry average
15%
234 trials in Phase 3/4
4%
14 of 318 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (1564)
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
Role: lead
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
Role: collaborator
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Role: lead
A Study of the Intervention of Time-restricted Eating in High-risk Populations of GDM
Role: lead
AI-Guided TURBT for Bladder Cancer
Role: lead
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Role: lead
GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
Role: lead
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Role: lead
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
Role: lead
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Role: lead
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer
Role: lead
First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients
Role: lead
MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancer
Role: lead
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
Role: lead
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Role: lead
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
Role: lead
Efficacy of Acupuncture for Postoperative Urinary Retention Following Radical Hysterectomy for Cervical Cancer
Role: collaborator
Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment
Role: lead
Real-World Study of Young Patients With Solid Tumors in China
Role: lead
Current Status and Determinants of Care for Patients With Acute Chest Pain in China: A Retrospective Analysis of Data From the China Chest Pain Center Registry
Role: collaborator